Not yet recruiting
Gastroenteropancreatic neuroendocrine tumour disease+5
Not yet recruitingRegistered drugNo placebo
Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment
Registered drugNo placebo
- Disease:Gastroenteropancreatic neuroendocrine tumour diseasePeritoneal mesothelioma malignant+4
- Substances:DomvanalimabFluorouracil+3
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Domvanalimab
- Sponsor:Hospices Civils De Lyon
